The gold-standard GLP-1 injectable for significant, sustained weight loss and metabolic improvement.
Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist that has transformed weight management for patients with PCOS and insulin resistance. By mimicking a natural hormone at far greater potency, it dramatically reduces appetite, improves insulin sensitivity, and delivers clinically proven weight loss of 15-20% of body weight.
Get Started
Ozempic is a brand-name injectable medication containing semaglutide, a GLP-1 receptor agonist. It belongs to the same drug class as Wegovy and was originally developed for type 2 diabetes management, but has become widely prescribed for weight loss due to its powerful appetite-suppressing and metabolic effects.
Administered as a once-weekly subcutaneous injection, Ozempic works by mimicking the GLP-1 hormone your body naturally produces after eating — but at much higher concentrations and with a much longer duration of action. This results in significant reductions in hunger, improved blood sugar control, and sustained weight loss that is difficult to achieve through diet and exercise alone.
For patients with PCOS, Ozempic addresses two of the most challenging aspects of the condition: insulin resistance and weight management — both of which drive the hormonal imbalances at the core of PCOS symptoms.
Get Started — $1,299/mo →Semaglutide targets multiple pathways simultaneously, creating a comprehensive approach to weight loss and metabolic health.
Mimics the natural GLP-1 hormone your body produces after eating, but at much higher potency and with a half-life of approximately one week — compared to the minutes that natural GLP-1 lasts.
Acts directly on the brain's hypothalamus to dramatically reduce hunger signals and food cravings. Patients consistently report feeling satisfied with smaller portions and reduced desire for high-calorie foods.
Improves insulin sensitivity, lowers fasting blood glucose, reduces inflammatory markers, and may improve cardiovascular health. These metabolic improvements persist even beyond the direct weight loss effects.
Food moves through the stomach more slowly, leading to prolonged feelings of fullness and satiety after meals. This natural slowing of digestion helps patients eat less without feeling deprived.
PCOS makes weight loss extremely difficult. Insulin resistance — present in up to 70% of PCOS patients — causes the body to store fat more readily and resist burning it. Traditional diets often fail because the hormonal environment actively works against weight loss. This creates a frustrating cycle that can feel impossible to break.
Semaglutide directly improves insulin sensitivity, reducing the elevated insulin levels that drive androgen production and PCOS symptoms.
Rather than relying on willpower, semaglutide biologically reduces hunger at the brain level — giving PCOS patients relief from the constant cravings that insulin resistance drives.
Ozempic simultaneously addresses insulin resistance and reduces appetite — attacking the two biggest barriers to weight loss in PCOS at the same time.
Both delivery methods use semaglutide, but they differ in convenience, dosing, and patient experience.
Semaglutide has been studied in multiple large-scale clinical trials, consistently demonstrating significant weight loss results.
Ozempic uses a gradual dose titration schedule to minimize side effects and help your body adjust.
Begin at the lowest dose (0.25 mg/week). You may notice mild appetite reduction. Some patients experience nausea as the body adjusts. Weight loss is typically minimal during this phase.
Dose increases to 0.5 mg/week. Appetite suppression becomes more noticeable. Most patients begin seeing measurable weight loss. Side effects from the initial phase typically improve.
Dose may increase to 1.0 mg/week based on response and tolerability. Significant appetite reduction and steady weight loss. Many patients report improved energy, better blood sugar levels, and reduced cravings.
Dose may reach up to 2.0 mg/week for maximum effect. Weight loss continues steadily. Full metabolic benefits — improved insulin sensitivity, better lipid profiles, reduced inflammation — become well established.
Inject into the abdomen (at least 2 inches from the navel), front of the thigh, or upper arm. Rotate injection sites each week to prevent irritation.
Pinch the skin at the injection site, insert the pen needle at a 90-degree angle, press the injection button, and hold for 6 seconds. The pen makes the process simple — no mixing or measuring required.
Pick a consistent day of the week for your injection. You can take it with or without food, at any time of day. Setting a weekly reminder helps maintain consistency.
Store unused pens in the refrigerator (36-46°F). Once in use, the pen can be kept at room temperature or refrigerated for up to 56 days. Do not freeze, and protect from direct heat and light.
GI side effects are most common during the first few weeks and during dose increases. The gradual titration schedule is designed to minimize these. Eating smaller, more frequent meals can help.
Your provider will monitor your progress and adjust dosing as needed. Report any persistent or severe symptoms promptly.
Clinical trials have shown average weight loss of 15-20% of body weight with semaglutide at therapeutic doses. Individual results vary based on starting weight, dose, diet, exercise, and metabolic factors. Most patients see noticeable results within the first 2-3 months, with weight loss continuing for 12-18 months.
Ozempic and Wegovy both contain semaglutide and work through the same mechanism. Wegovy is specifically FDA-approved for weight management at higher doses (up to 2.4 mg/week), while Ozempic is FDA-approved for type 2 diabetes (up to 2.0 mg/week). Both are frequently prescribed for weight loss, and the active ingredient is identical.
The gradual titration schedule (starting low and increasing every 4 weeks) allows your body to adjust to the medication and significantly reduces gastrointestinal side effects like nausea and vomiting. Patients who start at higher doses without titration experience much more severe side effects.
Yes, Ozempic and metformin are commonly prescribed together, especially for PCOS patients. They work through different mechanisms — metformin improves insulin sensitivity at the cellular level, while semaglutide works through appetite suppression and GLP-1 pathways. The combination can be more effective than either medication alone. Your provider will determine the right combination for you.
The Ozempic pen uses a very small, thin needle (similar to an insulin pen) that most patients describe as nearly painless — more like a brief pinch than a traditional injection. If needle anxiety is a concern, oral semaglutide drops are available as an alternative. Talk to your provider about which option is best for you.
Semaglutide helps maintain weight loss as long as you continue the medication, combined with healthy lifestyle habits. Research shows that discontinuing the medication can lead to weight regain, which is why many patients use it as part of a long-term treatment plan. Your provider will work with you to develop a sustainable approach.
Complete a 5-minute online consultation. A licensed provider will review your information within 1-2 business days.
Get Started — $1,299/monthFree shipping · Cancel anytime · No hidden fees